- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06178653
Two Different Treatment Modalities in Patients With Spinal Muscular Atrophy
Examining the Effects of Trunk Control Training and Pulmonary Rehabilitation Program in Children With Spinal Muscular Atrophy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bağcılar
-
Istanbul, Bağcılar, Turkey, 34214
- Medipol Mega University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Those with genetic documentation of 5q spinal muscular atrophy (SMA) homozygous gene deletion, mutation, or compound heterozygote and who have been clinically diagnosed with SMA,
- Those between the ages of 5-18,
- Maximum inspiratory capacity is less than 60 cmH2O,
- Children who can sit unsupported for at least 5 seconds and who have no or 3 weeks of acute reversible events affecting the upper respiratory tract.
Exclusion Criteria:
- Having had upper extremity and spine surgery,
- Having other orthopedic and neurological problems,
- Having cognitive impairments that may prevent understanding simple verbal commands,
- Having visual or auditory disabilities,
- Premature birth
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pulmonary Rehabilitation Group
The program will be carried out 5 days a week, 2 times a day for 8 weeks, one day in the clinic under the supervision of the researcher, and the other four sessions in the home under the supervision of the caregiver. Caregivers will also be taught respiratory rehabilitation techniques to apply at home. Pulmonary Rehabilitation Training Program consists of diaphragmatic breathing, Pursed-lip breathing, and segmental breathing. Inspiratory muscle training: In our research, IMT will be performed in a sitting position using a handheld threshold valve device (Orygen Inspiratory Valve) that offers an adjustable inspiratory resistance via a spring-loaded valve with variable pressure load adjustment from 0-70 cmH2O. Inspiratory muscle training will be applied by calculating 30% of the maximal inspiratory pressure (MIP). During weekly clinic visits, the MIP value will be recalculated and the current threshold pressure value will be determined. |
Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
|
|
Experimental: Trunk Control Training Group
The program will be carried out 3 days a week, with pulmonary rehabilitation in each session, for a total of 45-60 minutes, for 8 weeks.
The training of children whose evaluations are completed will begin after individually structured pulmonary rehabilitation and trunk control training programs are created.
The content of pulmonary rehabilitation will consist of diaphragmatic breathing, pursed-lip breathing, segmental breathing, and IMT.
Exercises and activities for trunk muscle activation, pelvic control, and proximal stabilization will be used together with trunk and gluteal muscle strengthening exercises.
The intensity and level of exercises will be increased gradually.
Body control work will first start on hard ground and then continue on soft ground and dynamic surfaces.
All trunk control training will be applied actively or actively assisted.
|
Pulmonary rehabilitation consists of diaphragmatic, pursed-lip, and segmental breathing techniques, and also included inspiratory muscle training (will adjust 30% of maximal inspiratory pressure value)
Trunk Control Exercises will be based on the neurodevelopmental process.
Exercises will progressively include activities such as stretching, turning, etc. while sitting on different surfaces (firm/soft).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inspiratory Muscle Strength
Time Frame: 8 weeks
|
Inspiratory Muscle Strength will be assessed by the Maximal Inspiratory Pressure (MIP).
For MIP measurement, participants will be asked to perform maximum inspiration starting from the residual lung volume following maximum expiration to the total lung capacity.
|
8 weeks
|
|
Expiratory Muscle Strength
Time Frame: 8 weeks
|
Expiratory Muscle Strength will be assessed by the Maximal Expiratory Pressure (MEP).
For MEP measurement, participants will be asked to exert maximum expiratory effort from total lung capacity to residual volume.
Pressure thresholds sustained for at least 1 second will be recorded.
The highest pressure value of these maneuvers, expressed in cmH2O, will be recorded.
|
8 weeks
|
|
Pulmonary Function Test
Time Frame: 8 weeks
|
Participants will be in a sitting position during spirometric measurement in accordance with the standards and recommendations of the American Thoracic Society and European Respiratory Society statement.
Forced vital capacity (FVC), volume of air exhaled in the 1st second of forced expiration (FEV1), FEV1/FVC ratio, peak expiratory flow (PEF) values of the participants will be measured through spirometric (Spirobank MIR, Italy) measurement.
At least three successful spirometric assessments will be recorded.
FVC is the volume of air exhaled rapidly and forcefully following deep inspiration.
PEF value is measured by maximum inspiration followed by maximum expiration.
It usually correlates with FEV1 measurements.
In the interpretation of spirometric tests, information can be obtained about the type and severity of respiratory dysfunction by looking at the shape and numerical parameters of the flow-volume and time curve.
|
8 weeks
|
|
Effectiveness of Cough
Time Frame: 8 weeks
|
The effectiveness of the cough will be evaluated with a Peak Flow meter.
This value provides us with information about the expiratory muscles.
To evaluate the ability to cough without assistance, the patient is asked to cough as hard as possible into a small handheld device called a peak flow meter (ExpiritePeak Flow Meter DL-F03) while in a sitting position.
This measured value is called peak cough flow (PCF).
These values will provide an indication of the patient's disease progression, ability to clear secretions, and risk of developing respiratory complications.
PCF is applied to children over the age of 4-8.
The expected value in healthy individuals is PCF ≥ 360 L/minute.
The fact that this value is 270 L/minute in children with DMD, another neuromuscular muscle disease, shows that participants have adequate cough.
A PCF value falling below 160 L/minute indicates inadequate airway clearance.
Absolute values will be determined by selecting the largest of three consecutive trials.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trunk Control
Time Frame: 8 weeks
|
Trunk Control will be assessed by Trunk Control Measurement Scale.
Children's trunk control levels will first be determined according to the Trunk Control Measurement Scale (TCMS), which was developed for children with cerebral palsy.
The TCMS consists of 15 items that evaluate 2 different parameters related to trunk control; One of the parameters is static sitting balance and the other is dynamic sitting balance.
It evaluates not only trunk control but also trunk compensation during limb movements.
Within dynamic sitting balance, balance parameters in reaching and reaching are also evaluated.
Total scores range from 0 to 58, with higher scores indicating good trunk control.
|
8 weeks
|
|
Upper Extremity Functions
Time Frame: 8 weeks
|
Upper Extremity Functions will be assessed by Revised Upper Limb Module for Spinal Muscular Atrophy.
The revised upper extremity module for SMA contains 19 items and is evaluated out of a total of 37 points.
The first item is not included in the scoring, and the remaining 18 items are evaluated between 0-2 points, except for item I, and only item I is evaluated between 0-1 points.
The module is calculated on a total of 37 points, higher scores indicate better upper extremity function.
|
8 weeks
|
|
Gross Motor Function
Time Frame: 8 weeks
|
Gross Motor Function levels will ve assessed by the Hammersmith Functional Motor Scale.
It measures the motor function changes of children with SMA who can and cannot walk.
It consists of 33 items that indicate the capacity to perform motor functions such as sitting on a chair without support, lying face down or rolling over, lifting the head from the prone position, and crawling.
Each activity, categorized into items, is scored on a 3-point system with 2 points for "performs without modification", 1 point for "performs with modification/adaptation/compensation" and 0 points for "cannot perform the task".
The maximum score on the scale is 66, and a higher score means better motor functions.
|
8 weeks
|
|
Quality of Life of the Children
Time Frame: 8 weeks
|
In evaluating the quality of life of patients with SMA; Pediatric Quality of Life Questionary-Generic Core (PedsQL-GC) will be used.
It questions the areas of physical health, emotional functionality, and social functionality, which are the characteristics of the state of health defined by the World Health Organization.
Items are scored between 0-100.
If the answer to the question is marked as never, it receives 0=100, if it is marked as rarely, it receives 1=75, if it is marked as sometimes, it receives 2=50, if it is marked as often, it receives 3=25, and if it is marked as almost always, it receives 4=0 points.
The total score is obtained by adding the points and dividing by the number of items completed.
If more than 50% of the scale is not filled out, the scale is not evaluated.
The higher the total score, the better the health-related quality of life is perceived.
|
8 weeks
|
|
Burden of Caregiver
Time Frame: 8 weeks
|
Caregiver burden score will be evaluated by the Zarit Caregiver Burden Interview.
It was developed by Zarit, Reever and Bach-Peterson in 1980.
It is a scale used to evaluate the distress experienced by caregivers of individuals in need of care.
The scale, which can be completed by asking the caregivers themselves or the researcher, consists of 19 statements that determine the impact of caregiving on the individual's life.
The scale has a Likert-type rating ranging from 1 to 5, such as never, rarely, sometimes, often or almost always.
A high scale score indicates that the distress experienced is high.
|
8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-10840098-772.02-198
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Atrophy, Spinal
-
Marco CapogrossoRoche-GenentechActive, not recruitingSpinal Muscular Atrophy | Spinal Muscular Atrophy Type 3 | SMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy 4United States
-
Hoffmann-La RocheActive, not recruitingSpinal Muscular Atrophy (SMA)United States, Spain, Canada, United Kingdom, Croatia, Australia, Netherlands, Japan, Poland, Belgium, Portugal, Italy
-
Institut de Myologie, FranceInstitut RocheCompletedType 2 Spinal Muscular Atrophy | Type 3 Spinal Muscular AtrophyBelgium, France, Germany
-
University Hospital, RouenAgence de La BiomédecineRecruitingSpinal Muscular Atrophy (SMA)France
-
Marco CapogrossoRoche-GenentechCompletedSpinal Muscular Atrophy Type 3 | Spinal Muscular Atrophy Type 4United States
-
BiogenNo longer availableInfantile-onset Spinal Muscular AtrophyNew Zealand, Colombia, Turkey (Türkiye)
-
Novartis Gene TherapiesCompletedGene Therapy | SMA - Spinal Muscular AtrophyUnited States
-
Peking University Third HospitalBeihang UniversityCompleted
-
Novartis Gene TherapiesActive, not recruitingSMA | Spinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type I | Spinal Muscular Atrophy Type IIIUnited States, Belgium, France, Japan, United Kingdom, Italy, Taiwan, Australia, Canada
-
Charitable Foundation Children with Spinal Muscular...P.V. Voloshyn Institute of Neurology, Psychiatry and Narcology of the National...RecruitingSpinal Muscular Atrophy (SMA)Ukraine
Clinical Trials on Pulmonary Rehabilitation
-
Faculty of Medicine, SousseCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
Universidade Federal de Santa MariaCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Beijing Chao Yang HospitalBeijing Municipal Health CommissionNot yet recruiting
-
Istanbul Medipol University HospitalRecruitingLung Diseases | Bronchiectasis | Lung Diseases, Interstitial | Pulmonary RehabilitationTurkey
-
University of EdinburghNot yet recruitingChronic Respiratory ConditionsCameroon, Nigeria, South Africa
-
Istanbul Medipol University HospitalCompletedEmphysema | Bronchoscopic Lung Volume Reduction | Hospital-based Pulmonary Rehabilitation | Home-based Pulmonary RehabilitationTurkey
-
The Children's Hospital of Zhejiang University...Not yet recruiting
-
ADIR AssociationEuropean Union; Hopital La Musse; Groupe Hospitalier du Havre; Centre Hospitalier... and other collaboratorsRecruitingChronic Obstructive Pulmonary Disease (COPD)France
-
La Trobe UniversityMonash University; The Alfred; Austin HealthCompletedChronic Obstructive Pulmonary DiseaseAustralia
-
Aveiro UniversityCentro Hospitalar do Baixo VougaRecruitingChronic Obstructive Pulmonary Disease | Interstitial Lung DiseasePortugal